Skip to content
Calculator

Grey-Market Encyclopedia · Hub

The grey market for peptides

What the grey market is, how it differs from a compounding pharmacy and from an approved drug, why people use it, and what they give up, laid out side by side. Neither a recommendation nor a warning: a description, with a source for every claim.

Last updated October 28, 2026 · Reviewed by Grey Peptides Editorial Board · ✓ Every claim sourced · No products sold, no seller named

Sub-page
Buyer's guide: start here
Twelve steps for a first-time buyer, each linking the page that covers it, with a printable checklist.
Sub-page
Physical risks
Wrong compound, wrong amount, contamination, endotoxin, sterility and injection reactions, from published tests and case reports.
Sub-page
Financial risks
No recourse, crypto-only payment, no chargebacks, exit scams, orders that never ship and seized parcels.
Sub-page
Legal risks
FDA status, what 'research use only' does and does not do, personal importation, customs, WADA and other countries.
Sub-page
How buyers find sellers, and the scams
The channels described generically, and the scams common to each.
Sub-page
The 2025 China crackdown
What was reported, and what happens to buyers when a supplier disappears.
Sub-page
Contamination and skin reactions
Reaction types, how to tell an infection from an expected reaction, and when to get care.
Sub-page
US warehouses and domestic stock
What domestic stock changes, and what it does not.
📋 Key takeaways

The grey market is the sale of peptides to the public outside licensed pharmacies: unapproved drugs, or copies of approved ones, usually labelled 'for research use only' or 'not for human consumption'. FDA says such labels have been used on products sold to consumers for human use with dosing instructions.1

People use it for reasons that are real: a lower price than prescription products,4 compounds that no regulator has approved for anyone,14 supply during shortages,56 and buying without a prescription or an appointment (our reasoning: a purchase with no prescriber leaves no prescription record and needs no visit).

What they give up is the checking a regulated product carries: identity, amount, sterility and endotoxin testing before release, a label that is accurate, and someone accountable when it goes wrong. Published tests of grey-market products found vials holding the right molecule in the wrong amount, and products holding a different molecule or none.8910

On this page

  1. What the grey market is
  2. How it differs from compounding pharmacies and approved drugs
  3. Why people use it
  4. The trade-offs, side by side
  5. The three kinds of risk
  6. Reading path
  7. Frequently asked questions
  8. Related on Grey Peptides
  9. Sources

What the grey market is

On this site, the grey market means peptides sold to the public outside licensed pharmacies and without a prescription: drugs that no regulator has approved, research compounds, and copies of approved drugs made by someone other than the approved manufacturer. The word grey is meant literally: the products are sold openly online, much like ordinary goods,12 but in the United States they are unapproved drugs when they are sold for people to take, and FDA warns the companies that sell them.1

Most grey-market vials carry a label saying they are for research use only or not for human consumption. FDA's position is that those labels do not decide what a product is: it has warned companies that sold drugs "falsely labeled 'for research purposes' or 'not for human consumption'" which were sold directly to consumers for human use with dosing instructions.1 Regulators in Canada and Australia say the same about the research-use label: Health Canada says it "does not make these products legal or exempt from regulatory requirements",7 and Australia's regulator says such disclaimers do not make supply lawful or permit importation.15 Our research-use-only article covers the label in full, and the legal risks page covers the law.

The market is not only American. Health Canada said in April 2026 that "unauthorized drug products are illegal in Canada" and that peptides there are generally regulated as prescription drugs.7 Researchers in Australia, Canada and the US described injectable peptides in JAMA in July 2026 as sold directly online through telehealth services and "research chemical" vendors, and widely promoted on social media.12 Most of the supply is made in China; our Chinese peptides article follows the trade data.

Its size is not measured directly. One window on it is payments: a blockchain analytics firm traced 32 million US dollars in cryptocurrency to wallets it attributes to grey-market peptide vendors in the first quarter of 2026, and projected a year above 100 million dollars.16 That covers crypto payments only, so it is a floor, not a total.

How it differs from compounding pharmacies and approved drugs

Three kinds of product can carry the same molecule's name. They differ in who made them, who checked them, and what a buyer can do when something is wrong.

Approved drugCompounded drug (US)Grey-market product
Reviewed by a regulator before saleYes: FDA approval of the productNo: "compounded drugs are not FDA-approved"2No1
Who makes itThe approved manufacturerA state-licensed pharmacy or physician (section 503A) or an FDA-registered outsourcing facility (503B)23Unknown to the buyer; usually a seller relabelling bulk material (see Chinese peptides explained)
PrescriptionRequired for prescription drugs503A requires a patient-specific prescription2None asked1
Manufacturing standardCurrent good manufacturing practice (CGMP)CGMP for 503B outsourcing facilities; not for 503A2None that a buyer can verify (our reasoning: nothing in the sale binds the maker to a standard)
What tests have foundThe genuine pen read 5% over its label in one study's method check8Two compounded semaglutide vials read 101% and 102% of their labels as received11Semaglutide 29% to 39% over label; retatrutide from about half to nearly double; some products with a different molecule or no protein at all8910
Who answers for itThe manufacturer, under its approvalThe pharmacy, under state and federal law2In practice, no one (see financial risks)

The line between the second and third columns moved in 2025. While semaglutide and tirzepatide were on FDA's shortage list, pharmacies could compound copies; FDA found the tirzepatide shortage resolved on December 19, 2024 and the semaglutide shortage on February 21, 2025, and the periods during which it would not act against compounders then ended in the first half of 2025.3 A nurse practitioners' journal reported in 2026 that affordability barriers after the shortages ended were pushing patients toward "research-grade" peptides bought online and toward unregulated providers.5

Why people use it

The reasons below are the ones published research and reporting describe. They are listed as reasons, not endorsements.

  • Cost. The New York Times reported in January 2026 that prescription GLP-1 drugs "could cost more than $1,000 per month until fairly recently" while research-use equivalents "went for one-fifth the cost", and that kits ordered directly from manufacturers in China cost 50 to 100 dollars each (news report).4 Ongoing affordability barriers are named as a driver toward online "research-grade" peptides in a 2026 clinical report.5
  • Access to compounds with no approved product. Some peptides people want have never been approved anywhere for human therapeutic use; WADA's 2026 Prohibited List names BPC-157 as one such substance.14 For those, there is no prescription route at all, so the grey market is the only source outside a clinical trial (our reasoning from that fact). Investigational drugs still in trials, such as retatrutide, are sold the same way; its maker says no medicine containing retatrutide has been approved for human use by any regulator.17
  • Shortages. A study of 3,748 comments under GLP-1 videos found users sharing ways to navigate cost, side effects and medication shortages.6 When a shortage ends, compounded copies stop as well,3 which a 2026 report links to a shift toward online research-grade products.5
  • Privacy. Buying without a prescription involves no prescriber, so no prescription record is created (our reasoning). Stigma is part of it: the Times found people using peptides for productivity more willing to speak publicly than people using them for weight loss, which it read as a sign of more stigma around weight, and one user worried that her use would affect her career (news report).4
  • Speed. There is no appointment, assessment or pharmacy step before an order (our reasoning). The JAMA authors describe these as "low-barrier access points".12

The trade-offs, side by side

Each reason to buy has a cost attached. This table sets them next to each other; the sub-pages give the evidence behind the right-hand column.

What the buyer getsWhat the buyer gives up
A lower price than the prescription product4Any assurance about content: published tests found labelled amounts off by large margins in both directions and some products with the wrong molecule or none8910
Compounds no regulator has approved, with no prescription route14Human evidence: for many such compounds there is little or none (each encyclopedia entry grades it), and athletes face anti-doping rules that ban non-approved substances at all times14
Supply when an approved product is short6The checks a regulated maker or pharmacy must pass before release2
No prescription record (our reasoning)No clinician deciding whether the drug suits the person, adjusting the dose or watching for harm; published case reports describe hospital admissions after unsupervised use of online products1819
No appointment or wait (our reasoning)Recourse: cryptocurrency payments "typically are not reversible" and "do not come with legal protections"20; prepaid orders can fail to arrive (see financial risks)
Delivery to the door from a seller anywhere (our reasoning)Legal exposure: in most circumstances it is illegal for individuals to import drugs for personal use, and refused parcels can be destroyed13 (see legal risks)

Buyers manage some of these costs themselves. Shared orders spread the price of laboratory testing; the Times described a buyer paying 250 dollars to have kits tested in Europe (news report).4 Testing a sample costs money and covers only the vial tested, so a buyer who does not test relies on the seller's own certificate (our reasoning). Our group-buys article covers what testing can and cannot catch.

The three kinds of risk

The risks fall into three groups, each with its own page:

Taking any peptide also carries the risks of the drug itself, which no source can remove. Those are on each compound's encyclopedia entry, and dose information, where a credible source gives one, is in each entry's dosing box rather than on these pages.

Reading path

Read in this order for the whole picture, from the label on the vial to what to do with one you already have. A first-time buyer should start with the buyer's guide, step one below:

  1. Buyer's guide: start here. Twelve steps for a first-time buyer, each linking the page that covers it, with a printable checklist.
  2. Physical risks. Wrong compound, wrong amount, contamination, endotoxin, sterility and injection reactions, from published tests and case reports.
  3. Financial risks. No recourse, crypto-only payment, no chargebacks, exit scams, orders that never ship and seized parcels.
  4. Legal risks. FDA status, what 'research use only' does and does not do, personal importation, customs, WADA and other countries.
  5. How buyers find sellers, and the scams. The channels described generically, and the scams common to each.
  6. The 2025 China crackdown. What was reported, and what happens to buyers when a supplier disappears.
  7. Contamination and skin reactions. Reaction types, how to tell an infection from an expected reaction, and when to get care.
  8. US warehouses and domestic stock. What domestic stock changes, and what it does not.
  9. What 'research use only' means. The label most grey-market vials carry, and what it does in law.
  10. Chinese peptides explained. Where most of the supply is made, the crypto trail and the testing data.
  11. Peptide raves and group buys. How buyers pool orders and testing, and what testing misses.
  12. Peptides on Amazon, Temu and TikTok Shop. What the marketplace listings are, the law and the tests.
  13. How to evaluate a peptide vendor. Certificates, purity and endotoxin: what a seller's paperwork can show.
  14. Purity is not safety. Endotoxin, heavy metals, TFA and sterility, and the limits approved injectables meet.
  15. Serious reactions to injected peptides. Published cases of harm after injected peptides, and FDA's immunogenicity warnings.
  16. Spot a fake COA in 60 seconds. A checklist for a certificate of analysis.
  17. Peptide package seized by customs? FDA notices, refusal and destruction, step by step.
  18. How to check a seller's claims. What a certificate, a lab test and a seller's numbers can and cannot tell you.
  19. Published test results. Independent lab results on peptide products, failures included.

Coming next in this section: Kits versus single vials; Bacteriostatic water. Each will appear here, and in the reading path above, when it is published.

Frequently asked questions

What is a grey-market peptide?

A peptide sold to the public outside a licensed pharmacy and without a prescription, usually labelled for research use only. In the US, FDA treats such products sold for people to take as unapproved drugs, whatever the label says.1

Is a compounded peptide the same as a grey-market one?

No. A compounded drug is made by a state-licensed pharmacy or physician on a patient-specific prescription, or by an FDA-registered outsourcing facility. It is not FDA-approved either, but it is made under pharmacy law by an accountable business.2

Why do people buy peptides on the grey market?

Mainly price, compounds with no approved product, shortages of approved drugs, privacy and speed. Reporting and research describe price and access as the main drivers.4512

Does Grey Peptides recommend or name grey-market sellers?

No. The site sells nothing, names no seller and links to none. These pages describe how the market works and what published tests and regulators have found.

Unfamiliar word? All grey-market terms in the glossary, from kit, group buy and reshipper to chargeback, de minimis and import alert, each with its source. On every page in this section, the first use of a defined term links to its definition.

Buyer's guide: start here Physical risks Financial risks Legal risks How buyers find sellers, and the scams The 2025 China crackdown Contamination and skin reactions US warehouses and domestic stock What 'research use only' means Chinese peptides explained Peptide raves and group buys Peptides on Amazon, Temu and TikTok Shop How to evaluate a peptide vendor Purity is not safety Grey-market glossary

Sources

Regulators' pages are quoted with the date they show; peer-reviewed papers were read at PubMed; news is labelled as news. All read October 28, 2026 unless a source says otherwise.

  1. U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. Content current as of October 1, 2026; read October 28, 2026. Source
  2. U.S. Food and Drug Administration. Compounding Laws and Policies (sections 503A and 503B of the FD&C Act). Content current as of December 17, 2024; read October 28, 2026. Source
  3. U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (tirzepatide shortage resolved December 19, 2024; semaglutide February 21, 2025). Content current as of April 1, 2026; read October 28, 2026. Source
  4. Sun J, Henry J, Agosta H. 'Chinese Peptides' Are the Tech World's Latest Biohacking Fad. The New York Times, January 3, 2026, republished by GV Wire, January 7, 2026. News report; read October 28, 2026. Source
  5. Trainer N. The "microdosing" dilemma: Balancing patient anecdotes with clinical safety amid GLP-1 compounding restrictions. J Am Assoc Nurse Pract. 2026. PMID 42201545. Source
  6. Ugwu H, Willis E, Pickett M. Electronic word-of-mouth and off-label use of Ozempic and other GLP-1 medications. J Health Psychol. 2026;31(11):4349-4363. PMID 41604144. Source
  7. Health Canada. Think twice before injecting peptides bought online: unauthorized products can seriously harm your health. Public advisory, April 9, 2026; read October 28, 2026. Source
  8. Ashraf AR, et al. Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study. J Med Internet Res. 2024;26:e65440. PMID 39509151. Source
  9. Piatkowski T, Craven A, Cornell S, Ferris J. Composition and Labelling Accuracy of Products Sold as Retatrutide in Australia. Drug Alcohol Rev. 2026;45(6):e70231. PMID 42559975. Source
  10. Reichel C, Filip T, Gmeiner G, Thevis M. Gel Electrophoretic Detection of Black Market ACE-031. Drug Test Anal. 2025;17(10):1934-1946. PMID 40312924. Source
  11. Kopp KL, et al. Impurities and Potential Immunogenicity Associated With Follow-on and Compounded Glucagon-like Peptide-1 Receptor Agonists. Pharm Res. 2026;43(8):2861-86. PMID 42533250. The study was funded by the maker of the originator product. Source
  12. Piatkowski T, Ganson KT, Nagata JM. Illicit Injectable Peptides and Regulatory Gaps. JAMA. 2026;336(3):189-190. PMID 42295803. Quotations from the University of Toronto's release on the paper, June 15, 2026. Source
  13. U.S. Food and Drug Administration. Personal Importation. Content current as of August 18, 2025; read October 28, 2026. Source
  14. World Anti-Doping Agency. The 2026 Prohibited List, in force January 1, 2026: S0, non-approved substances ('no current approval by any governmental regulatory health authority for human therapeutic use'), naming BPC-157. Read October 28, 2026.
  15. Therapeutic Goods Administration (Australia). Understanding your responsibilities when importing, compounding and supplying unapproved peptide products. Safety alert, no date shown; read October 28, 2026. Source
  16. Chainalysis Team. The $100 Million Crypto 'Looksmaxxing' Boom: How Chinese Cartel Suppliers Pivoted to the Gray-Market Peptide Ecosystem. Chainalysis blog, June 4, 2026; figures as reported by Decrypt, June 4, 2026 (news report). Read October 28, 2026. Source
  17. Eli Lilly and Company. Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market. News release, August 12, 2026 (the manufacturer; Standing rule 3 (h)). Read October 28, 2026. Source
  18. Sterckx M, De Keyser L. Euglycemic Ketoacidosis Following the Use of Counterfeit Semaglutide for Weight Loss. Cureus. 2026;18(1):e102627. PMID 41773123. Source
  19. Branine N. Online-Sourced Retatrutide Complicating Impending Diabetic Ketoacidosis in a Patient With Type 1 Diabetes and Concurrent Shigella Gastroenteritis. Cureus. 2026;18(8):e115260. PMID 42669023. Source
  20. Federal Trade Commission. What To Know About Cryptocurrency and Scams. Consumer advice, last modified February 10, 2025; read October 28, 2026. Source

This page describes how the grey market works; it is not legal or medical advice, and it is not a guide to buying. Grey Peptides sells nothing, links to no seller and rates none. If you have taken a product and feel unwell, contact a clinician or Poison Help (1-800-222-1222 in the US).